PharmacoLearnIt’s Important to Know!

Daily Pharma News - 23 October 2026

Welcome to PharmacoLearn's daily pharma news round-up. Today's stories span drug quality enforcement in Delhi, new national prescribing guidelines from the Health Ministry and the Indian Pharmacopoeia Commission, India's first dual-target CAR-T cell therapy for multiple myeloma, a major immunology discovery from Hyderabad's CCMB, China's first anti-FcRn biologic for myasthenia gravis, a WHO alert on Ebola in Nigeria, and a new US lung cancer launch from AstraZeneca. Read on for what each development means for pharmacy students and practising pharmacists in India.

Delhi Drug Control Report: Quality Lapses Found at 44 Factories and 1,807 Retail Outlets

The Delhi drug control department has reported significant compliance gaps in its 2025-26 inspection drive, with violations detected at 44 of the 371 manufacturing units inspected and at approximately 1,807 of 5,902 retail outlets. Of the 735 drug samples drawn for quality testing, only 427 met prescribed standards, a finding that raises serious questions about adherence to Good Manufacturing Practice (GMP) norms and retail licensing conditions in the national capital.

For pharmacy students, this report is a textbook case study in why the Drugs and Cosmetics Act, 1940, Schedule M requirements, and state drug control inspections exist. Drug inspectors are the first line of defence against substandard and spurious medicines reaching patients. The data point that over 300 samples failed quality standards is a reminder that quality assurance in the pharmaceutical industry is not paperwork; it is patient safety. Students preparing for GPAT or preparing for careers in regulatory affairs and QA/QC should note how enforcement data like this feeds into policy decisions on licensing and surveillance.

Health Ministry and IPC Issue New Guidelines for Safer, Rational Drug Prescriptions

The Union Health Ministry and the Indian Pharmacopoeia Commission (IPC) have jointly issued prescribing guidance anchored in the National Formulary of India (NFI) 2026, aimed at curbing overprescribing, guiding the rational use of antibiotics and painkillers, and promoting the prescription of generic medicines under the Pradhan Mantri Bhartiya Janaushadhi Pariyojana (Jan Aushadhi) scheme.

This development sits at the heart of rational drug use, a core concept in clinical pharmacy and pharmacology. Antimicrobial resistance (AMR) driven by antibiotic misuse is one of the WHO's top global health threats, and prescription discipline is its primary countermeasure. For pharmacy students, the NFI 2026 linkage matters: the National Formulary lists essential medicines and their rational-use guidance, and pharmacists are expected to counsel patients and support prescribers on generic substitution, appropriate dosage, and duration of therapy. Expect this topic to appear in pharmacology, pharmacy practice, and public health examinations.

Nucelion and VeGen Bio to Manufacture India's First Dual-Target CAR-T Therapy for Multiple Myeloma

In a landmark for Indian cell and gene therapy, Bharat Biotech's Nucelion Therapeutics will manufacture VeGen Bio's VL-2511, described as India's first dual-target CAR-T cell therapy for multiple myeloma. The Hyderabad-based partners are targeting an Indian Phase 1/2 clinical trial and commercialisation by 2028. VL-2511 is a dual BCMA/CD19 autologous CAR-T product designed to improve depth and durability of response in relapsed or refractory multiple myeloma.

CAR-T cell therapy represents one of the most significant advances in modern oncology pharmacy, and India's entry into indigenous CAR-T manufacturing has the potential to bring costs down dramatically from imported therapies. The dual-target design (BCMA and CD19) is scientifically notable: targeting two antigens simultaneously aims to reduce antigen escape, a well-known mechanism of relapse after single-target CAR-T. For students, this story connects immunology, biotechnology, biopharmaceutical manufacturing, and the regulatory pathway for advanced therapy medicinal products in India. It also highlights Hyderabad's growing role as a cell-therapy manufacturing hub.

CSIR-CCMB Hyderabad Discovers DZIP3, a Cellular Alarm Switch That Fights Viruses

Scientists at the CSIR-Centre for Cellular and Molecular Biology (CCMB) in Hyderabad have identified the protein DZIP3 as a key sensor of viral RNA that triggers type-I interferon responses at mitochondria. The pathway conferred protection against SARS-CoV-2, chikungunya virus, and Japanese encephalitis virus in experimental models, marking DZIP3 as a previously underappreciated component of innate immunity.

This is high-value reading for pharmacology and immunology students because innate immune sensing is the biological foundation of antiviral drug design and vaccine adjuvant science. Proteins that detect viral nucleic acids, such as RIG-I and MDA5, are already therapeutic targets; DZIP3 may join that list as a future target for broad-spectrum antiviral strategies. The fact that the mechanism converges on mitochondria also ties into cell-signalling topics covered in molecular pharmacology courses. Research breakthroughs like this frequently surface in competitive examinations as statement-based questions on the researchers, the institute, and the mechanism involved.

China's NMPA Approves Batoclimab (Enlida), First Anti-FcRn Therapy for Myasthenia Gravis

China's National Medical Products Administration (NMPA) has approved batoclimab, marketed as Enlida, for adult generalised myasthenia gravis. The approval makes it the first anti-FcRn biologic available in China. In a 27-centre Phase III trial, 58.2 percent of batoclimab-treated patients achieved sustained MG-ADL improvement compared with 31.3 percent on placebo, a statistically significant result (P = 0.001).

Myasthenia gravis is an autoimmune neuromuscular disorder driven by pathogenic autoantibodies, and the FcRn (neonatal Fc receptor) is a well-validated target: blocking it accelerates the clearance of those autoantibodies. Globally, anti-FcRn therapies such as efgartigimod and rozanolixizumab have already reshaped treatment, and China's approval of a domestic product is significant for access and pricing in the region. For Indian pharmacy students, this is a strong example of biologics pharmacology in action, monoclonal antibody mechanism of action, and how regulators like the NMPA, FDA, EMA, and CDSCO evaluate immunoglobulin-lowering therapies for orphan and autoimmune indications.

WHO Confirms No Licensed Vaccine or Treatment Exists for Bundibugyo Ebola Strain

The World Health Organization has confirmed that Nigeria's first Ebola case in a decade is caused by the Bundibugyo strain, for which no licensed vaccine or treatment currently exists. The case was detected 13 days after the patient fell ill, a delay that complicates contact tracing and outbreak containment across the region.

Ebola virus disease management differs sharply by strain: licensed vaccines and monoclonal antibody therapies such as those used in recent Zaire-strain outbreaks are not approved for Bundibugyo, a critical distinction that pharmacy students should memorise. This story illustrates the role of the WHO in outbreak surveillance, the pharmacology of filovirus therapeutics, and the public-health importance of early detection. For Indian students, the broader lesson is preparedness: understanding emerging infectious diseases, travel-related risk, and the regulatory status of vaccines and therapeutics is central to public health pharmacy and hospital pharmacy practice.

AstraZeneca Launches Zegfrovy (Sunvozertinib) in the US for EGFR Exon 20 Insertion Lung Cancer

AstraZeneca has launched Zegfrovy (sunvozertinib) in the United States for patients with previously treated non-small cell lung cancer (NSCLC) harbouring EGFR exon 20 insertion mutations. The drug received accelerated approval based on a 46 percent overall response rate and an 11.1-month median duration of response.

EGFR exon 20 insertions are a distinct molecular subtype of NSCLC that responds poorly to earlier-generation EGFR tyrosine kinase inhibitors (TKIs) such as erlotinib and osimertinib, making selective agents like sunvozertinib clinically important. For pharmacy students, this launch connects molecular oncology, precision medicine, biomarker-driven prescribing, and the concept of accelerated approval based on surrogate endpoints. Understanding mutation-specific therapy selection, resistance mechanisms, and the pharmacist's role in managing TKI toxicities and drug interactions is increasingly essential as targeted oncology agents expand in India too.

Conclusion

Today's news captures the full breadth of modern pharmacy, from enforcement and prescribing discipline in India to cutting-edge cell therapy, immunology, biologics, and global outbreak response. The common thread is the pharmacist's evolving role: guardian of drug quality, partner in rational prescribing, interpreter of new biotechnology, and frontline responder in public health. For students, the most exam-relevant takeaways are the NFI 2026 prescribing guidelines, the DZIP3 innate-immunity mechanism, the dual-target CAR-T design rationale, the anti-FcRn mechanism of batoclimab, and the strain-specific gaps in Ebola vaccines and therapies. Stay consistent with your daily reading, and these stories will compound into deep, examination-ready knowledge.

References

  1. ETV Bharat - Delhi drug control report https://www.etvbharat.com/en/bharat/delhi-drug-control-department-uncovers-major-lapses-in-drug-manufacturing-and-retail-sales-enn26102202447
  2. Mint - Health Ministry and IPC prescribing guidelines https://www.livemint.com/news/drug-prescriptions-pharma-use-health-ministry-ipc-11792668660806.html
  3. ETV Bharat - Nucelion and VeGen Bio dual-target CAR-T https://www.etvbharat.com/en/bharat/bharat-biotech-nucelion-vegen-bio-target-2028-launch-for-indias-first-dual-target-car-t-therapy-for-myeloma-enn26102202196
  4. The Hindu - CSIR-CCMB DZIP3 discovery https://www.thehindu.com/news/national/telangana/csir-ccmb-scientists-uncover-key-protein-that-helps-cells-detect-and-fight-viruses/article71611571.ece
  5. TipRanks - HBM Holdings NMPA approval for batoclimab https://www.tipranks.com/news/company-announcements/hbm-holdings-wins-nmpa-approval-for-first-fcrn-biologic-in-china
  6. Reuters - WHO Ebola Nigeria alert https://www.reuters.com/business/healthcare-pharmaceuticals/late-detection-nigeria-raises-alarm-ebola-spreads-across-africa-2026-10-22/
  7. AstraZeneca (Business Wire) - Zegfrovy US launch https://www.businesswire.com/news/home/20261022931109/en/ZEGFROVY-sunvozertinib-now-available-in-the-US-for-patients-with-previously-treated-non-small-cell-lung-cancer-with-EGFR-exon-20-insertion-mutations

← All daily news